research Epidemiology and treatment modalities for the management of benign prostatic hyperplasia
More men are getting benign prostatic hyperplasia, and there are many treatments, from medication to surgery, with new methods being developed.
Search
for
Sort by
Research
300-330 / 1000+ results 
research 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.
research The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer
Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
research Frontal fibrosing alopecia: A retrospective review of 19 patients seen at Duke University
Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
research Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician
Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
research Combined C3b and Factor B Autoantibodies and MPGN Type II
The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.
research Primary cicatricial alopecia
Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.
research Ethanol Enhances Neurosteroidogenesis in Hippocampal Pyramidal Neurons by Paradoxical NMDA Receptor Activation
Ethanol boosts brain steroid production by activating NMDA receptors, affecting memory formation.
research Hair Loss in Women
Effective hair loss treatment in women requires correct diagnosis and can include medications like minoxidil, antiandrogens, and treatments for underlying conditions like PCOS.
research 5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection
5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction, but the exact reasons are unclear.
research Emerging medication for the treatment of male hypogonadism
New treatments for male hypogonadism are effective and should be personalized.
research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
research Frontal fibrosing alopecia: clinical and prognostic classification
Researchers found three patterns of Frontal fibrosing alopecia, with Pattern III having the best prognosis after treatment.
research Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
S5αR inhibitors might help treat schizophrenia and other mental disorders but need more research.
research Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.
research Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research 5alpha-reductase: history and clinical importance.
5alpha-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT, offering symptom relief and potential future uses.
research Pattern Hair Loss in Men
Male pattern hair loss caused by follicular miniaturization; early diagnosis and treatment can reduce psychological burden.
research Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials
5α-reductase inhibitors increase the risk of sexual dysfunction, especially in men with enlarged prostate.
research 5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes
Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
research A review of the treatment of male pattern hair loss
Finasteride and minoxidil work best together for hair loss.
research Androgens and hair loss
The document concludes that hair transplantation and gene therapy may be important for future hair loss treatment.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
Certain drugs that block specific enzymes can help treat prostate diseases.
research Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
Non-binary transgender individuals need personalized hormonal treatments for better well-being and quality of life.
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research Actions of 5α-reductase inhibitors on the epididymis
5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
research 5 Alpha-reductase inhibitors: whatʼs new?
A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
research Clinical application of 5α-reductase inhibitors
5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
research Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti‐androgens
Hair loss treatments work better with lifestyle changes.
research 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.